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Abstract: Diabetic patients with hypertension are approximately twice as likely to develop 
cardiovascular disease as non-diabetic patients with hypertension. Given that hypertension 
affects ∼60% of patients with diabetes, effective blood pressure (BP) management is important 
in this high-risk population. This post-hoc analysis pooled data from six clinical studies to 
quantify additional BP efficacy achieved when titrating hypertensive diabetic patients from 
amlodipine 5 mg to 10 mg. Approximately half of the diabetic patients were male (44/98; 44.9%) 
with a mean (standard deviation [SD]) age of 60.6 (9.6) years and a baseline mean (standard 
error [SE]) systolic blood pressure/diastolic blood pressure (SBP/DBP) of 150.8 (1.30)/87.5 
(0.94) mmHg while on amlodipine 5 mg (159.1 [1.40]/92.6 [0.94] mmHg prior to treatment). 
In comparison, 350/610 (57.4%) non-diabetic patients were male with a mean (SD) age of 58.7 
(11.1) years and baseline mean (SE) SBP/DBP of 150.3 (0.62)/90.9 (0.41) mmHg while on 
amlodipine 5 mg (160.0 [0.67]/96.2 [0.45] mmHg prior to treatment). Increasing amlodipine 
from 5 mg to 10 mg lowered sitting SBP by −12.5 mmHg (95% confidence interval (CI): −15.5, 
−9.5; P,0.0001) and DBP by −6.0 mmHg (−7.4, −4.6; P,0.0001) in diabetic patients; and SBP 
by −12.4 mmHg (−13.5, −11.3; P,0.0001) and DBP by −7.3 mmHg (−8.0, −6.7; P,0.0001) 
in non-diabetic patients. In total, 12.0% (95% CI: 6.4, 20.0) of diabetic patients achieved their 
BP goal versus 46.4% (42.4, 50.4) of non-diabetic patients after titration to amlodipine 10 mg. 
Overall, 22.0% of diabetic patients experienced 31 adverse events (AEs) and 28.9% of non-
diabetic patients experienced 282 AEs. Serious AEs were reported by one (1.0%) diabetic and 
five (0.8%) non-diabetic patients. In this analysis, increasing amlodipine from 5 mg to 10 mg 
produced a clinically significant reduction in the BP of diabetic hypertensive patients, similar 
to non-diabetic patients, highlighting the importance of optimizing amlodipine titration in this 
high-risk population.
Keywords: hypertension, diabetes, calcium channel blockers, cardiovascular disease 
prevention, efficacy
Background
Hypertension and diabetes each represent a major public health challenge worldwide. 
They frequently co-exist, thus compounding the risk of vascular morbidity and mor-
tality associated with these conditions individually. The worldwide prevalence of 
hypertension in the year 2000 was estimated to be 26.4% (972 million adults), with a 
predicted rise of approximately 60% to a total of 1.56 billion adults (29.2%) by 2025.1 
Recent estimates put global diabetes prevalence in the year 2011 at 8.3% (366 million 
adults), increasing to 9.9% (552 million adults; approximately 50% rise) by 2030.2
Higher levels of blood pressure (BP) are a powerful predictor of cardiovascular 
disease (CVD), including coronary heart disease (CHD) and stroke.3,4 Hypertension Vascular Health and Risk Management 2014:10 submit your manuscript | www.dovepress.com
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affects approximately 60% of patients with diabetes,5 and is 
twice as likely to occur in diabetic patients compared with 
their age-matched non-diabetic counterparts.6 Compared 
with diabetic individuals who are normotensive, those with 
concomitant hypertension exhibit about a two-fold increase 
in the risk of cardiovascular events and death.7–9 Moreover, 
hypertension has been found to be a stronger predictor of 
cardiovascular events as compared with diabetes.9
Given the high prevalence of hypertension in diabetic 
patients, combined with the observed increased cardio-
vascular risk attributable to hypertension, appropriate BP 
management strategies should be employed to mitigate the 
risk of future CVD events. The Joint National Committee 
on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure (JNC 8) advocate a sitting BP goal of 
140/90 mmHg for hypertensive patients with diabetes and/or 
chronic kidney disease patients.10 Similarly, the American 
Diabetes Association (ADA) guidelines and joint guide-
lines from the European Society of Hypertension (ESH)/
European Society of Cardiology (ESC) recommend a BP 
goal of ,140/80 mmHg11 and ,140/85 mmHg,12 respec-
tively, for patients with diabetes. The caveat is that a lower 
systolic blood pressure (SBP) target (ie, ,130 mmHg) 
may be appropriate for some diabetic individuals, such as 
younger patients or those at higher risk of stroke, if it can 
be achieved with fewer drugs and without adverse effects.11 
A similarly revised BP goal of ,140/85 mmHg has been 
proposed for those with diabetes in the latest joint guide-
lines for hypertension management from the ESH/ESC.12 
However, effective therapeutic control of BP in patients with 
concomitant diabetes and hypertension can be challenging, 
and many patients are not achieving desired BP goals despite 
antihypertensive medication use.13–18
Antihypertensive regimens based on angiotensin-
  converting-enzyme inhibitors (ACEIs), angiotensin II recep-
tor blockers (ARBs), calcium channel blockers (CCBs), 
and diuretics/beta-blockers are all broadly comparable for 
reducing cardiovascular risk in patients with and without 
diabetes.19 Amlodipine (Pfizer Inc., New York, NY, USA) 
is a well-established, long-acting CCB for the treatment of 
hypertension, including patients with diabetes.20–22 Studies 
in hypertensive patients have highlighted the additional ben-
efit of titrating amlodipine from 5 mg to 10 mg once daily 
with regard to lowering BP,23–27 including Asian patients.26 
However, because the efficacy of increasing amlodipine dose 
from 5 mg to 10 mg has thus far only been evaluated in a 
small number of patients with hypertension and diabetes, 
we conducted this post-hoc analysis of 710 patients with 
known diabetic status from six clinical trials, which included 
100 diabetic patients. The objective of this analysis was to 
assess the incremental effect of amlodipine titration to 10 mg 
daily on BP-lowering efficacy in patients with concomitant 
diabetes and hypertension who had not responded sufficiently 
to treatment with the 5 mg dose.
Methods
Study selection criteria
Studies selected for this analysis were all Pfizer-
  sponsored studies of amlodipine treatment for mild to 
moderate hypertension for which there was patient-level 
data, diabetic status was known, and dose was titrated 
from 5 mg to 10 mg.
Study design and participants
This post-hoc analysis used pooled data from six random-
ized controlled or open-label clinical studies assessing the 
efficacy and safety of amlodipine 5 mg daily titrated to 
10 mg daily in patients with mild or moderate hypertension 
(Table 1). Although total study durations varied depending 
on the design, patients in this analysis received amlodipine 
at a dose of 5 mg daily for 4–8 weeks followed by titration 
up to 10 mg daily as required for an additional 4–8 weeks. 
Patients were stratified into two subgroups based on their 
diabetes status at the time of entry into the study (those with 
diabetes versus those without diabetes), derived from their 
medical history.
Study endpoints and assessments
Efficacy endpoints were change from baseline in sitting SBP 
and diastolic blood pressure (DBP) to the specified time point, 
and proportion of patients who achieved the sitting BP goal at 
follow-up. Depending on the study, sitting BP was measured 
once or twice at each visit. Each patient’s response for a given 
visit was the average of the multiple measurements, or the 
single measurement if only one sitting BP was available. 
The sitting BP goal was ,130/80 mmHg for patients with 
diabetes and ,140/90 mmHg for patients without diabetes. 
The BP goal was also assessed according to recently revised 
guidelines of a sitting BP goal of ,140/80 mmHg (ADA 
guidelines)11 and a sitting BP goal for age ,60 years, 
140/90 mmHg; age $60 years, 150/90 mmHg (JNC 8 
guidelines)10 for both subgroups.
Safety endpoints were frequency of treatment-emergent 
adverse events (AEs) (all causality), treatment-emergent Vascular Health and Risk Management 2014:10 submit your manuscript | www.dovepress.com
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Table 1 Studies used in the pooled analysisa
Study Design Study number/
NCT number  
(if applicable)
With  
diabetes 
(N=100)
Without 
diabetes 
(N=610)
Patient population Total  
study  
durationb
Study dates
1 Randomized,  
multicenter, double- 
blind, parallel group
a0531004c 10 70 Washed out of antihypertensives  
or treatment naïve
18 weeks 6 March 2001– 
14 October 2003
2 single arm, multicenter, 
open, non-interventional
a0531044c 38 134 Washed out of antihypertensives  
or treatment naïve
12 weeks 1 November 2001– 
31 March 2002
3 Randomized,  
multicenter, double- 
blind, parallel group
a0531085 
ncT00415623
26 125 Uncontrolled on current  
antihypertensive at screening,  
doses stable throughout the study
16 weeks 6 January 2007– 
20 October 2007
4 Single arm, long-
term extension for 
ncT00415623
a0531086 
ncT00443456
12 57 Uncontrolled on current  
antihypertensive at screening,  
doses stable throughout the study
44 weeks 2 May 2007– 
11 June 2008
5 Randomized,  
multicenter, double- 
blind, parallel group
a053R0510c 12 121 Washed out of antihypertensives  
or treatment naïve
18 weeks Study dates 
unavailable
6 single arm, multicenter, 
open, non-interventional
AML-NY-93002c 2 103 Uncontrolled on current  
antihypertensive at screening,  
doses stable throughout the  
study, or treatment naïve
14 weeks 20 November  
1993–30 april  
1995
Notes: aAll Pfizer-sponsored studies of amlodipine treatment for mild to moderate hypertension for which there were patient-level data, diabetic status was known, and 
dose was titrated from 5 mg to 10 mg; bwhere applicable, total study duration included screening, baseline, and multiple study phases; cthese trials started before September 
2008, before clinical studies were registered at http://www.clinicaltrials.gov; NCT Number, ClinicalTrials.gov Identifier.
serious AEs (all causality), and AEs resulting in withdrawal 
from treatment (all causality).
Statistical analyses
Patients without a diabetes status at study entry were excluded 
from the analysis. The efficacy analysis included all patients 
in the intent-to-treat population who received at least one dose 
of amlodipine, were titrated from 5 mg to 10 mg daily, and 
had both a baseline and at least one follow-up BP measure-
ment (last observation carried forward analysis). The safety 
analysis included all patients who received a least one dose of 
amlodipine and were titrated from 5 mg to 10 mg daily.
Baseline values were established while patients were on 
amlodipine 5 mg treatment (ie, prior to amlodipine titra-
tion). Baseline characteristics were compared between the 
two subgroups using analysis of variance for numeric vari-
ables with study and subgroup in the model, and using the 
Cochran–Mantel–Haenszel statistic stratified by study for 
dichotomous variables. Blood pressure data were analyzed 
using descriptive statistics, paired Student’s t-tests, and cor-
responding confidence intervals (CIs). An exact CI based 
on the binomial distribution was used for the proportion of 
responders. The proportion of common AEs was compared 
between subgroups using the Cochran–Mantel–Haenszel 
statistic stratified by study. Given the sparseness of events 
across studies, a corresponding unconditional exact CI was 
calculated on the pooled data using the statistical software 
StatXact Version 10 by Cytel (Cambridge, MA, USA).28 All 
tests used an alpha of 0.05 with corresponding 95% CIs.
Results
Study population
A total of 710 patients with known diabetic status were 
included in this analysis (693 with complete BP data). Of 
the 100 patients (14.1%) with diabetes at study entry, four 
patients (4.0%) discontinued from the study; all four dis-
continuations were due to AEs. Of the 610 patients (85.9%) 
without diabetes at study entry, 44 patients (7.2%) discon-
tinued from the study. Reasons for discontinuation among 
non-diabetic patients included: AEs (n=33; 5.4%), no longer 
willing to participate (n=4; 0.7%), protocol violation (n=2; 
0.3%), insufficient clinical response (n=1; 0.2%), and other 
reason (n=4; 0.7%).
Patients with diabetes were mostly female (55.1%) with 
a mean (standard deviation [SD]) age of 60.6 (9.6) years 
and a baseline mean (standard error [SE]) SBP/DBP prior 
to amlodipine treatment of 159.1 (1.40)/92.6 (0.94) mmHg 
(Table 2); mean (SE) SBP/DBP was 150.8 (1.30)/87.5 (0.94) 
mmHg while on amlodipine 5 mg treatment. Patients without 
diabetes were mostly male (57.4%) with a mean (SD) age of 
58.7 (11.1) years and a baseline mean (SE) SBP/DBP prior 
to amlodipine treatment of 160.0 (0.67)/96.2 (0.45) mmHg Vascular Health and Risk Management 2014:10 submit your manuscript | www.dovepress.com
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(Table 2); mean (SE) SBP/DBP was 150.3 (0.62)/90.9 (0.41) 
mmHg while on amlodipine 5 mg treatment. Patients with 
diabetes weighed more and had a higher body mass index 
than their non-diabetic counterparts (Table 2).
Blood pressure levels and goal attainment
In patients with diabetes, titration of amlodipine 5 mg to 10 mg 
lowered sitting SBP by –12.5 mmHg (95% CI: −15.5, −9.5; 
P,0.0001) and DBP by −6.0 mmHg (95% CI: −7.4, −4.6; 
P,0.0001) from baseline (established while patients were 
on amlodipine 5 mg treatment) to follow-up (Figure 1A). 
Mean (SE) SBP/DBP at follow-up in diabetic patients was 
138.3 (1.35)/81.5 (0.86) mmHg. Similarly, in patients with-
out diabetes, titration to amlodipine 10 mg lowered sitting 
SBP by −12.4 mmHg (95% CI: −13.5, −11.3; P,0.0001) 
and DBP by −7.3 mmHg (95% CI: −8.0, −6.7; P,0.0001) 
from baseline (established on amlodipine 5 mg treatment) to 
follow-up (Figure 1B). Mean (SE) SBP/DBP at follow-up in 
non-diabetic patients was 137.9 (0.56)/83.5 (0.36) mmHg.
Not surprisingly, fewer patients with diabetes achieved 
their desired BP goal compared with non-diabetic patients. 
In total, 12/100 patients with diabetes (12.0%; 95% CI: 
6.4, 20.0) attained a BP ,130/80 mmHg; 283/610 patients 
without diabetes (46.4%; 95% CI: 42.4, 50.4) attained a 
BP ,140/90 mmHg. Slightly more diabetic patients (25/100 
[25%; 95% CI: 16.9, 34.7]) achieved the newly revised ADA 
target BP levels of ,140/80 mmHg. Even more diabetic 
patients (64/100 [64%; 95% CI: 53.8, 73.4]) achieved the 
new JNC 8 target BP goals of 140/90 (aged ,60 years) or 
150/90 (aged $60 years) mmHg.
Safety
Overall, 22/100 patients with diabetes (22.0%) experienced 
31 AEs and 176/610 patients without diabetes (28.9%) 
experienced 282 AEs (Table 3). The AEs most frequently 
reported by patients with diabetes were: peripheral edema 
(n=4; 4.0%), sinusitis (n=2; 2.0%), and upper respiratory tract 
infection (n=2; 2.0%). The AEs most frequently reported 
by patients without diabetes were: peripheral edema (n=46; 
7.5%), nasopharyngitis (n=24; 3.9%), back pain (n=8; 1.3%), 
and upper respiratory tract infection (n=6; 1.0%).
Serious AEs were reported by one patient (0.1%) with 
diabetes (event: ankle fracture) and five patients (0.8%) 
without diabetes (events: cardiomyopathy, pneumonia, facial 
bone fracture, intervertebral disk protrusion, gingival cancer, 
cerebrovascular accident, cerebrovascular disorder, Table 3). 
Three patients with diabetes (3.0%) and 20 patients without 
diabetes (3.3%) withdrew from treatment due to an AE 
(Table 3). Adverse events that led to treatment withdrawal 
in patients with diabetes included: peripheral edema (n=1; 
1.0%), headache (n=1; 1.0%), and hypertension (n=1; 1.0%). 
AEs that led to treatment withdrawal in patients without dia-
betes included: peripheral edema (n=8; 1.3%), joint swelling 
(n=2; 0.3%), and dyspnea (n=2; 0.3%).
Discussion
This retrospective, pooled analysis has shown that increas-
ing amlodipine from 5 mg to 10 mg daily provided a clini-
cally and statistically significant incremental reduction in 
sitting SBP and DBP in patients with concomitant diabetes 
and hypertension who had not responded sufficiently to 
treatment with the 5 mg dose. Furthermore, the incre-
mental benefit on BP lowering achieved with amlodipine 
titration was similar in both diabetic and non-diabetic 
patient populations. This is similar to what has previously 
been observed in other patient populations, such as Asian 
patients with hypertension.26 Amlodipine 10 mg was also 
well tolerated in patients with diabetes, demonstrating a 
safety profile similar to that observed in the non-diabetic 
patient group and previous studies involving high-dose 
amlodipine.23,24,26,29,30
Table 2 Baseline characteristics of the study population stratified 
by diabetes status
Characteristic With 
diabetes 
(N=100)
Without 
diabetes 
(N=610)
Male, n (%) 44 (44.9)a,* 350 (57.4)
Mean age, years (SD) 60.6 (9.64) 58.7 (11.08)
Mean SBP/DBP, mmHg (SE) 159.1 (1.40)/ 
92.6 (0.94)*
160.0 (0.67)/ 
96.2 (0.45)
Mean weight, kg (SD) 82.1 (16.80)* 75.4 (16.68)
Mean BMi, kg/m2 (SD) 30.3 (4.60)* 27.0 (4.36)
History of CHD, n (%) 7 (7.0) 24 (3.9)
Prior antihypertensive use, n (%) 64 (64.0) 312 (51.1)
    Prior antihypertensive use by class, n (%)b
    acei 42 (42.0) 139 (22.8)
    aRB 4 (4.0) 49 (8.0)
      alpha receptor agonist/antagonist 2 (2.0) 10 (1.6)
      Alpha2-Adrenergic Agonist 1 (0.2)
      BB 14 (14.0) 64 (10.5)
      ccB 37 (37.0) 140 (23.0)
      Centrally-acting antihypertensive 5 (5.0) 8 (1.3)
      Diuretics 10 (10.0) 80 (13.1)
      ergot alkaloid 1 (0.2)
      Vasodilator 1 (0.2)
Notes:  an=98 (two patients with sex not specified);  bpatients could have been 
taking more than one medication; *P,0.05.
Abbreviations: BMI, body mass index; CHD, coronary heart disease; DBP, diastolic 
blood pressure; SBP, systolic blood pressure; SD, standard deviation; SE, standard 
error; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor 
blocker; BB, beta blocker; CCB, calcium channel blocker.Vascular Health and Risk Management 2014:10 submit your manuscript | www.dovepress.com
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Figure 1 Sitting blood pressure at baseline and follow-up in (A) patients with diabetes and (B) patients without diabetes titrated from amlodipine 5 mg to 10 mg.
Notes: Analyses were conducted using the intent-to-treat population. Baseline was established while patients were on amlodipine 5-mg treatment; follow-up was determined 
using a last-observation-carried-forward analysis.
Abbreviations: BP, blood pressure; CI, confidence interval.
The age-adjusted prevalence of diagnosed diabetes in the 
general US adult population has recently been estimated at 
8.5%.31 However, in this analysis, diabetes prevalence in this 
patient population with mild or moderate hypertension was 
nearly double that of the current national estimate, at 14.1%. 
Patients with hypertension have been shown to have a 2.5-fold 
excess risk of developing diabetes over 6 years of follow-up 
compared with non-hypertensive individuals (relative risk: 
2.43; 95% CI: 2.16, 2.73).32 Similarly, hypertension is twice 
as likely to occur in patients with diabetes versus those Vascular Health and Risk Management 2014:10 submit your manuscript | www.dovepress.com
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Table 3 Incidence of all-cause adverse events in patients with and without diabetes titrated from amlodipine 5 mg to 10 mg
Parameter With diabetes 
(N=100)
Without diabetes 
(N=610)
Difference  
(%)b
95% CIb
Number of AEs 31 282
Patients with aes, n (%) 22 (22.0) 176 (28.9)
Patients with serious aes, n (%) 1 (1.0) 5 (0.8)
Patients withdrawn from treatment  
due to aes, n (%)
3 (3.0) 20 (3.3)
Most common aesa, n (%) 
    Back pain 
Nasopharyngitis 
Peripheral edema 
sinusitis 
Upper respiratory tract infection
 
0 (0.0) 
0 (0.0) 
4 (4.0) 
2 (2.0) 
2 (2.0)
 
8 (1.3) 
24 (3.9) 
46 (7.5) 
0 (0.0) 
6 (1.0)
 
−1.3 
−3.9* 
−3.5 
2.0* 
1.0
 
[−2.7, 2.1] 
[−5.9, −0.5] 
[−7.3, 2.3] 
[ 0.2, 7.0] 
[−1.0, 5.6]
Notes: Analyses were conducted using the safety population. Baseline was established while patients were on amlodipine 5 mg treatment. *P,0.05, null hypothesis is that 
the percentage of patients with the given AE is equal between the two subgroups, versus not equal; athose with an incidence .1.0% in either subgroup; bdifference between 
the two subgroups in the percentage of most common AEs (those with diabetes minus those without), and associated 95% confidence interval.
Abbreviations: AEs, adverse events; CI, confidence interval.
without diabetes, with prevalence in diabetic patients of 
approximately 60%.5,6 Although hypertension and diabetes 
individually predict cardiovascular morbidity and mortal-
ity, the concomitance of these two conditions only serves 
to exacerbate the cardiovascular risk associated with either 
condition in isolation.7–9 Hence, appropriate management of 
cardiovascular risk factors, with particular emphasis on the 
early detection and effective treatment of hypertension in 
patients with diabetes, is paramount to reduce CVD burden 
in these high-risk individuals.
Even modest reductions in BP have the potential to 
substantially reduce cardiovascular morbidity and mortality. 
A meta-analysis of data from 61 prospective observational 
studies on deaths from vascular disease among individu-
als with no known vascular disease at baseline found that 
a 2 mmHg reduction in SBP could lower mortality from 
stroke by 10% and from ischemic heart disease or other vas-
cular causes by 7%.4 Similarly, the results of a prospective, 
observational study in patients with diabetes showed that a 
10 mmHg decrease in SBP was associated with reductions in 
the risk of diabetes-related complications (including myo-
cardial infarction, sudden death, angina, and stroke; rela-
tive risk reduction: 12%; 95% CI: 10%, 14%; P,0.0001), 
diabetes-related deaths (including death from myocardial 
infarction, sudden death, and stroke; relative risk reduction: 
15%; 95% CI: 12%, 18%; P,0.0001), and myocardial 
infarction (relative risk reduction: 11%; 95% CI: 7%, 14%; 
P,0.0001).33 Thus, the observed incremental reduction in 
BP by uptitrating amlodipine to 10 mg (−12.5 mmHg in 
SBP, −6.0 mmHg in DBP) in diabetic patients would be 
expected to drastically reduce the occurrence of diabetes-
related complications.
Numerous clinical trials of antihypertensive agents have 
demonstrated the benefit of BP lowering on cardiovascu-
lar outcomes in a range of patient populations, including 
patients with diabetes.34–36 The UK Prospective Diabetes 
Study compared tight control of BP to ,150/85 mmHg 
with less rigorous control of BP to ,180/105 mmHg in 
hypertensive patients with diabetes.34 Patients allocated to 
tight BP control experienced a 24% reduction in the rela-
tive risk of diabetes-related endpoints (including sudden 
death, myocardial infarction, angina, and stroke; 95% CI: 
8%, 38%; P=0.0046), a 32% reduction in diabetes-related 
deaths (including death from myocardial infarction, sudden 
death, and stroke; 95% CI: 6%, 51%; P=0.019), and a 44% 
reduction in the risk of stroke (95% CI: 11%, 65%; P=0.013) 
compared with patients allocated to less rigorous BP control. 
The Action in Diabetes and Vascular Disease: Preterax 
and Diamicron MR Controlled Evaluation (ADVANCE) 
trial demonstrated that significant reductions in SBP and 
DBP (−5.6 mmHg and −2.2 mmHg, respectively; both 
P,0.001) to mean follow-up levels of 134.7/74.8 mmHg 
reduced the relative risk of major macrovascular or micro-
vascular events (including CVD death, non-fatal stroke, 
and non-fatal myocardial infarction) by 9% (hazard ratio 
[HR]: 0.91; 95% CI: 0.83, 1.00; P=0.04), and CVD death 
by 18% (HR: 0.82; 95% CI: 0.68, 0.98; P=0.03).35 A sub-
group analysis of 1,501 patients with diabetes enrolled in 
the Hypertension Optimal Treatment (HOT) trial, where 
hypertensive patients were randomly assigned to a target 
DBP, showed that the risk of major cardiovascular events 
(non-fatal myocardial infarction, non-fatal stroke, and 
cardiovascular death) was halved in those randomized to 
a DBP #80 mmHg compared with #90 mmHg (relative Vascular Health and Risk Management 2014:10 submit your manuscript | www.dovepress.com
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risk for 90 mmHg versus 80 mmHg: 2.06; 95% CI: 1.24, 
3.44; P for trend =0.005).36
However, recent results from the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD)37 and Interna-
tional Verapamil SR-Trandolapril Study (INVEST)38 trials 
have questioned the clinical benefit obtained with aggressive 
control of SBP levels to ,120 mmHg, or even ,130 mmHg. 
For example, the ACCORD trial, where patients with diabetes 
were randomized to a SBP ,120 mmHg versus ,140 mmHg, 
failed to demonstrate a significant reduction in the relative 
risk of major cardiovascular events, although a significant 
reduction in the relative risk of stroke was observed (HR: 
0.59; 95% CI: 0.39, 0.89; P=0.01).37 Moreover, the incidence 
of serious AEs attributed to antihypertensive treatment was 
significantly higher in the intensive-therapy group (3.3%) 
compared with the standard-therapy group (1.3%; P,0.001), 
indicating the potential for harm with aggressive BP lowering 
to within the normotensive range in this patient population. 
With this in mind, recent updates to treatment guidelines for 
the management of BP in patients with diabetes have seen 
therapeutic targets revised to ,140/80 mmHg (ADA),11 
or ,140/85 mmHg (ESH/ESC),12 with the option of a lower 
SBP goal (ie, ,130 mmHg) for some individuals, such as 
younger patients or those at very high risk of stroke, if it can 
be achieved with few drugs and without adverse effects.11
For patients with diabetes, current clinical practice guide-
lines advocate the use of renin–angiotensin system (RAS) 
inhibitors such as an ACEI or an ARB, with the addition 
of a CCB such as amlodipine, and/or hydrochlorothiazide, 
as needed to achieve BP goals.11 Studies in hypertensive 
patients have highlighted the incremental benefit of titrat-
ing amlodipine up to 10 mg on BP lowering.23–26 Moreover, 
higher doses of amlodipine have been shown to be equally 
effective or superior, either as monotherapy or in combina-
tion with another agent, in reducing cardiovascular out-
comes compared with other treatment regimens,39–42 even 
in patients with diabetes.16 The Avoiding Cardiovascular 
Events Through Combination Therapy in Patients Living 
With Systolic Hypertension (ACCOMPLISH) trial16 dem-
onstrated that combination therapy with benazepril and 
amlodipine (mean achieved BP: 131.5/72.6 mmHg) reduced 
the relative risk of a cardiovascular event (cardiovascular 
death, myocardial infarction, stroke, hospitalization for 
angina, resuscitated arrest, and coronary revascularization) 
by 21% compared with benazepril and hydrochlorothiazide 
(mean achieved BP: 132.7/73.7 mmHg) in patients with 
concomitant diabetes and hypertension (HR: 0.79; 95% CI: 
0.68, 0.92; P,0.003).
This analysis of pooled data from trials investigating the 
incremental effect of amlodipine titration to 10 mg daily on 
BP-lowering efficacy in patients with concomitant diabetes 
and hypertension has revealed that increasing amlodipine 
from 5 mg to 10 mg daily significantly lowered sitting SBP 
by −12.5 mmHg and DBP by −6.0 mmHg. Reductions in 
SBP and DBP of this magnitude are likely to translate to 
meaningful clinical reductions in cardiovascular outcomes 
in this high-risk patient group, however, the lack of informa-
tion on cardiovascular events is an obvious limitation of this 
study. Nevertheless, the ability to increase amlodipine dose 
may provide a safe and effective strategy through which to 
achieve an incremental improvement in BP levels before 
adding to the medication burden of this patient group, where 
the average number of antihypertensive medications used to 
achieve BP goals may be as high as 4.3.43
Conclusion
This retrospective, pooled analysis demonstrates that a signifi-
cant, incremental improvement in sitting SBP and DBP levels 
can be safely achieved in patients with and without concomi-
tant diabetes and hypertension by increasing amlodipine dose 
from 5 mg to 10 mg once daily. Thus, the use of amlodipine as 
a therapeutic option can be extended in the effective manage-
ment of hypertension in patients with diabetes.
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